Biostatistics and tumor marker studies in breast cancer: Design, analysis and interpretation issues

International Journal of Biological Markers

Volumn 18, Issue 1, 2003, Pages 40-48

  Biganzoli, Elia ^a   Boracchi, P ^b   Marubini, E ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FLUOROURACIL; GROWTH FACTOR RECEPTOR; HORMONE; METHOTREXATE; PREDNISONE; TUMOR MARKER;

BIOSTATISTICS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RESEARCH; CANCER RISK; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG RESPONSE; HUMAN; METHODOLOGY; ONCOGENE C ERB; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PREDICTION; PROGNOSIS; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL CONCEPTS; STATISTICAL PARAMETERS; TREATMENT OUTCOME;

EID: 0142217965     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.3652     Document Type: Conference Paper

References (21)

1. Bast RC Jr, Ravdin P, Hayes DF, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1865-78.
2. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn H-J. Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. J Clin Oncol 2001; 19: 3817-27.
3. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994; 69: 979-85.
4. Altman DG, Lyman GH. Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 1998; 52: 289-303.
5. Pajak TF, Clark GM, Sargent DJ, McShane LM, Hammond ME. Statistical issues in tumor marker studies. Arch Pathol Lab Med 2000; 124: 1011-5.
6. Clark GM. Interpreting and integrating risk factors for patients with primary breast cancer. J Natl Cancer Inst Monogr 2001; 17-21.
7. Paradiso A, Volpe S, Iacobacci A, et al. Quality control for biomarker determination in oncology: The experience of the Italian Network for Quality Assessment of Tumor Biomarkers (INQAT). Int J Biol Markers 2002; 17: 201-14.
8. Biganzoli E, Boracchi P, Daidone MG, Gion M, Marubini E. Flexible modelling in survival analysis. Structuring biological complexity from the information provided by tumor markers. Int J Biol Markers 1998; 13: 107-23.
9. Cox D. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34: 187-200.
10. Boracchi P, Biganzoli E, Marubini E. Joint modelling of cause specific hazard functions with cubic splines: An application to a large series of breast cancer patients. Comp Statistics Data Analysis 2002 (in press).
11. Biganzoli E, Boracchi P, Marubini E. A general framework for neural network models on censored survival data. Neural Networks 2002; 15: 49-58.
12. Hayes DF, Trock B, Harris AL. Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful? Breast Cancer Res Treat 1998; 52: 305-19.
13. Boracchi P, Biganzoli E. Markers of prognosis and response to treatment: Ready for clinical use in oncology? A biostatistician's viewpoint. Int J Biol Markers 2003 (in press).
14. Menard S, Valagussa P, Pilotti S, et al. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol 2001; 19: 329-35.
15. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001; 19: 2334-56.
16. Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992; 10: 599-605.
17. Miles DW, Harris WH, Gillett CE, Smith P, Barnes DM. Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. Int J Cancer 1999; 84: 354-9.
18. Schoenfeld D. The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika 1981; 68: 316-9.
19. Marubini E. Evidenza scientifica e statistica in la salute tra informazione e prova scientifica. In: Gallo C, Signoriello G, eds. SISMEC Conference Proceedings, 2001; 11-8.
20. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992; 10: 1049-56.
21. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 966-78.